In the absence of IL-21 conditioning, the mesothelin601-615 peptide induced the strongest IFN-γ responses in peripheral blood of patients with pancreatic cancer, as compared to the precursor mesothelin peptide mix, the mature mesothelin peptide mix or the control mesothelin586-600 peptide (Supplementary Table 1). The gene discussed is MSLN; the disease is pancreatic neoplasm.